A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity.

[1]  T. Oh,et al.  Construction and Manipulation of a New Kaposi's Sarcoma-Associated Herpesvirus Bacterial Artificial Chromosome Clone , 2012, Journal of Virology.

[2]  D. Gutmann,et al.  Deconvoluting mTOR biology , 2012, Cell cycle.

[3]  L. Aaltonen,et al.  KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. , 2011, Cell host & microbe.

[4]  S. Oakes,et al.  Multiple Defects, Including Premature Apoptosis, Prevent Kaposi's Sarcoma-Associated Herpesvirus Replication in Murine Cells , 2011, Journal of Virology.

[5]  Zhigang Zhang,et al.  Latent KSHV infection increases the vascular permeability of human endothelial cells. , 2011, Blood.

[6]  D. Dittmer.  Restricted Kaposi’s Sarcoma (KS) Herpesvirus Transcription in KS Lesions from Patients on Successful Antiretroviral Therapy , 2011, mBio.

[7]  F. Zhu,et al.  Phosphorylation of Eukaryotic Translation Initiation Factor 4B (EIF4B) by Open Reading Frame 45/p90 Ribosomal S6 Kinase (ORF45/RSK) Signaling Axis Facilitates Protein Translation during Kaposi Sarcoma-associated Herpesvirus (KSHV) Lytic Replication* , 2011, The Journal of Biological Chemistry.

[8]  D. Ganem,et al.  Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. , 2011, Journal of virological methods.

[9]  D. Ganem,et al.  Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. , 2011, Virology.

[10]  Ethel Cesarman,et al.  Kaposi's sarcoma and its associated herpesvirus , 2010, Nature Reviews Cancer.

[11]  D. Ganem,et al.  Viral latency and its regulation: lessons from the gamma-herpesviruses. , 2010, Cell host & microbe.

[12]  D. Ganem,et al.  The Lytic Transcriptome of Kaposi's Sarcoma-Associated Herpesvirus Reveals Extensive Transcription of Noncoding Regions, Including Regions Antisense to Important Genes , 2010, Journal of Virology.

[13]  D. Ganem.  KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. , 2010, The Journal of clinical investigation.

[14]  D. Ganem,et al.  Array-Based Transcript Profiling and Limiting-Dilution Reverse Transcription-PCR Analysis Identify Additional Latent Genes in Kaposi's Sarcoma-Associated Herpesvirus , 2010, Journal of Virology.

[15]  F. Zhu,et al.  Mechanism of Sustained Activation of Ribosomal S6 Kinase (RSK) and ERK by Kaposi Sarcoma-associated Herpesvirus ORF45 , 2009, Journal of Biological Chemistry.

[16]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[17]  Sang Gyun Kim,et al.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.

[18]  Philippe P Roux,et al.  Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation , 2008, Current Biology.

[19]  Ling Wang,et al.  Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. , 2008, Cancer research.

[20]  Qiyi Tang,et al.  Activation of p90 Ribosomal S6 Kinase by ORF45 of Kaposi's Sarcoma-Associated Herpesvirus and Its Role in Viral Lytic Replication , 2007, Journal of Virology.

[21]  S. Rafii,et al.  In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. , 2007, Cancer cell.

[22]  Ling Wang,et al.  Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. , 2007, Blood.

[23]  P. Biberfeld,et al.  Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development , 2006, International journal of cancer.

[24]  M. Skobe,et al.  Activation of NF-κB by the Latent vFLIP Gene of Kaposi's Sarcoma-Associated Herpesvirus Is Required for the Spindle Shape of Virus-Infected Endothelial Cells and Contributes to Their Proinflammatory Phenotype , 2006, Journal of Virology.

[25]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[26]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[27]  Steven P Gygi,et al.  Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Vieira,et al.  Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. , 2004, Virology.

[29]  Jay W. Shin,et al.  Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma–associated herpesvirus , 2004, Nature Genetics.

[30]  S. Henderson,et al.  Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma , 2004, Nature Genetics.

[31]  E. Sausville,et al.  Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Ganem,et al.  Lytic KSHV infection inhibits host gene expression by accelerating global mRNA turnover. , 2004, Molecular cell.

[33]  B. Damania,et al.  The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Activates the Akt Signaling Pathway , 2004, Journal of Virology.

[34]  D. Ganem,et al.  Host Range of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Cells , 2003, Journal of Virology.

[35]  E. Hafen,et al.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. , 2003, Molecular cell.

[36]  D. Dittmer.  Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. , 2003, Cancer research.

[37]  E. Cesarman,et al.  The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells , 2003, Journal of Virology.

[38]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[39]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[40]  D. Levy,et al.  A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  F. Zhu,et al.  Identification of the Immediate-Early Transcripts of Kaposi’s Sarcoma-Associated Herpesvirus , 1999, Journal of Virology.

[42]  A. Palestine,et al.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. , 1999, The New England journal of medicine.

[43]  M. Mildner,et al.  Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[44]  R. Sun,et al.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Cesarman,et al.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.

[46]  E. Cesarman,et al.  Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation , 1997, Nature.

[47]  B. Dezube.  Clinical presentation and natural history of AIDS--related Kaposi's sarcoma. , 1996, Hematology/oncology clinics of North America.

[48]  M. McGrath,et al.  Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.

[49]  C. Boshoff,et al.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells , 1995, Nature Medicine.

[50]  P. Moore,et al.  Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. , 1995, The New England journal of medicine.

[51]  G. Crabtree,et al.  Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.

[52]  V. Beral,et al.  Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? , 1990, The Lancet.

[53]  JohnJ. Brooks.  KAPOSI'S SARCOMA: A REVERSIBLE HYPERPLASIA , 1986, The Lancet.

[54]  Baig Ar,et al.  Sex-chromatin values in rat epithelium. , 1967 .

[55]  D. Ganem,et al.  Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. , 2004, The Journal of clinical investigation.

[56]  D. Ganem,et al.  The biology of Kaposi's sarcoma. , 2001, Cancer treatment and research.

[57]  K. Bhalla,et al.  Induction of human herpesvirus-8 DNA replication and transcription by butyrate and TPA in BCBL-1 cells. , 1999, The Journal of general virology.